The Cancer Immunotherapy group led by prof. dr. Karine Breckpot studies strategies to enhance immune cells’ ability to identify, surveil, and finally destroy cancer cells. Together with assistant-professor dr. Cleo Goyvaerts, the group studies mechanisms of resistance to immunotherapy. Platforms such as mRNA, lentiviral vectors, and single domain antibodies next to 3D tumor spheroids, organoids and mouse cancer models are used for these purposes. Strategies that are successful in the preclinical stage are translated towards phase I/II clinical trials.
